-+ 0.00%
-+ 0.00%
-+ 0.00%
Wanbang Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 96.4726 million yuan, a year-on-year increase of 54.14%; net profit to mother of 434,400 yuan, a year-on-year decrease of 93.10%; and net loss of 2.9076 million yuan after deducting non-return to mother. The first three quarters of 2026 achieved operating income of 184 million yuan, a year-on-year decrease of 12.03%; net profit to mother of 572,300 yuan, a year-on-year decrease of 98.27%; net loss of 163.385 million yuan after deducting non-return to mother.
Share
Listen to the news
Wanbang Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 96.4726 million yuan, a year-on-year increase of 54.14%; net profit to mother of 434,400 yuan, a year-on-year decrease of 93.10%; and net loss of 2.9076 million yuan after deducting non-return to mother. The first three quarters of 2026 achieved operating income of 184 million yuan, a year-on-year decrease of 12.03%; net profit to mother of 572,300 yuan, a year-on-year decrease of 98.27%; net loss of 163.385 million yuan after deducting non-return to mother.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending